This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Today's Health Winners and Losers

Shares of Nastech Pharmaceutical (NSTK) were among the worst-performing health-related stocks Thursday, plunging 37% after the company reacquired the rights to an obesity treatment that its partner, Merck (MRK), said doesn't work.

Merck terminated its agreement with Nastech after it concluded, through a preliminary study, that Nastech's nasal spray did not demonstrate efficacy. Despite Merck's decision to pull out of the collaboration, Nastech said that it plans to move ahead with the development of the obesity treatment.

"Based on our review, Nastech believes that clinical trial results to date support the continued development of this important investigational product for the treatment of obesity, and we remain committed to the further advancement of the PYY clinical program this year," Nastech said in a statement. Because of the termination, Nastech expects to recognize about $3.7 million in revenue during the first quarter. Shares recently were trading down $8.59 to $14.43.

Inhibitex (INHX) rose 2% after the biotechnology firm posted a narrower-than-expected fourth-quarter loss. The company reported a loss of $9.5 million, or 31 cents a share, on revenue of $162,500. Analysts polled by Thomson First Call expected a loss of 37 cents a share on revenue of $190,000. A year earlier, the company recorded a loss of $8.2 million, or 37 cents a share, on sales of $162,500. Shares were trading up 19 cents to $8.16.

Shares of BioDelivery Sciences (BDSI) sank 27% after the specialty biopharmaceutical company said the Food and Drug Administration issued a nonapprovable letter for Emezine, the company's treatment for nausea and vomiting.

The letter "stated that additional information would be required to address remaining questions," BioDelivery said. "We are extremely surprised and disappointed by the FDA's decision in light of the fact that we strictly adhered to the development program that was outlined in our pre-NDA meeting with the FDA in March of 2004." The company plans to meet with the FDA and will use the outcome of the meeting to determine its direction with Emezine. Shares were down 83 cents to $2.30, while shares of Accentia Biopharmaceuticals (ABPI), BioDelivery's distribution partner, fell 64 cents to $6.91.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs